Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus KEFZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME IN DEXTROSE CONTAINER versus KEFZOL.
CEFTAZIDIME IN DEXTROSE CONTAINER vs KEFZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1-2 g intravenously every 8 hours.
1-2 g IV/IM every 8 hours for moderate to severe infections; maximum 12 g/day.
None Documented
None Documented
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
1.5-2 hours in adults with normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minimal (<5%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic